PAX5 and neoplasm: In preleukemic mice, conditional Pax5 deletion cooperated with E2A-PBX1, leading to an increased leukemia penetrance and shortening its latency [58], hence confirming a tumor-suppressive role for Pax5 in an E2A-PBX1 background.